MAI Capital Management’s Neuropace NPCE Stock Holding History

MAI Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-171	Closed	-$2.25K	–	3791
2026 Q1	$2.25K	Buy	+171	New	+$2.56K	﹤0.01%	3875

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

MAI Capital Management's NPCE Position: Q2 2026 in Review

MAI Capital Management sold out of Neuropace (NPCE) in Q2 2026, closing a stake of 171 shares — an estimated $2.25K sold.

MAI Capital Management first reported a position in NPCE in Q1 2026 and held it in 1 quarter. The position peaked at $2.25K in Q1 2026. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

MAI Capital Management reported no remaining Neuropace position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 171 Neuropace shares in Q2 2026, an estimated $2.25K.
MAI Capital Management first reported a position in Neuropace in Q1 2026 and held it in 1 quarter.
MAI Capital Management's Neuropace position peaked at $2.25K in Q1 2026.
113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.